ATP7B Antibody

What is ATP7B and why is it important in biomedical research?

ATP7B (ATPase copper transporting beta) is a copper-transporting P-type ATPase that plays a crucial role in copper homeostasis, primarily in the liver. This 157.3 kDa transmembrane protein facilitates the excretion of excess copper from cells, particularly from hepatocytes into bile . ATP7B dysfunction due to genetic mutations leads to Wilson disease, a disorder characterized by toxic copper accumulation in tissues, resulting in hepatic and neurological damage . The protein is most abundant in liver and kidney tissues, with some expression in the brain . Understanding ATP7B biology is essential for elucidating copper metabolism disorders and developing potential therapeutic interventions for Wilson disease.

What types of ATP7B antibodies are available for research, and how do they differ?

ATP7B antibodies come in various formats optimized for different experimental applications:

Researchers should select antibodies based on their experimental needs, considering factors such as target epitope, species reactivity, and intended application . Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes, potentially providing stronger signals but with increased background risk.

What are the optimal conditions for using ATP7B antibodies in Western blotting?

When performing Western blot analysis with ATP7B antibodies, researchers should consider these methodological guidelines:

• Sample preparation: ATP7B is a membrane-associated protein, so use appropriate lysis buffers containing detergents (e.g., Triton X-100) to efficiently extract the protein from cellular membranes.

• Protein loading: Load 20-50 μg of total protein per lane for detection of endogenous ATP7B expression.

• Gel selection: Use lower percentage (6-8%) SDS-PAGE gels to properly resolve the high molecular weight (157 kDa) ATP7B protein.

• Transfer conditions: Perform transfer to nitrocellulose or PVDF membranes at lower voltage for extended periods (e.g., 30V overnight) to ensure complete transfer of this large protein.

• Blocking and antibody dilution: Most ATP7B antibodies work optimally at dilutions between 1:2000-1:5000, though this varies by manufacturer . For example, Proteintech's ATP7B-specific antibody (19786-1-AP) can be used at dilutions ranging from 1:5000 to 1:50000 for Western blotting .

• Expected band size: ATP7B typically appears at approximately 150-157 kDa, though some tissue-specific variations may occur .

Best results are typically obtained using liver tissue samples or hepatocyte cell lines like HepG2, which naturally express higher levels of ATP7B .

How can ATP7B antibodies be effectively used for immunolocalization studies?

For successful immunolocalization of ATP7B using immunofluorescence (IF) or immunohistochemistry (IHC):

• Fixation method: PFA fixation followed by Triton X-100 permeabilization is effective for cellular localization studies, as demonstrated in studies of RH-30 cells .

• Antigen retrieval: For paraffin-embedded tissues, use TE buffer at pH 9.0 or alternatively citrate buffer at pH 6.0 for optimal epitope exposure .

• Antibody dilution: For immunofluorescence, most ATP7B antibodies work effectively at 1:200-1:800 dilutions, while IHC applications may require 1:50-1:500 dilutions .

• Co-localization markers: To study subcellular localization, consider co-staining with organelle markers such as:

  • Rab7 and NPC1 for late endosomes

  • Lamp1 for lysosomes/late endosomes

  • GalT for Golgi apparatus

• Visualization systems: For fluorescent detection, Alexa Fluor-conjugated secondary antibodies provide excellent signal-to-noise ratio.

Researchers have successfully used this approach to demonstrate that ATP7B primarily localizes to the late endosomes and trans-Golgi network, with its distribution changing in response to cellular copper levels .

How can ATP7B antibodies contribute to Wilson disease diagnosis?

ATP7B antibodies have shown significant potential for improving Wilson disease (WD) diagnosis, addressing limitations of current diagnostic methods:

• Direct measurement approach: Immunoaffinity enrichment mass spectrometry using ATP7B antibodies enables quantification of ATP7B peptides from dried blood spots (DBS), providing direct evidence of ATP7B deficiency .

• Diagnostic performance: ATP7B peptide analysis demonstrates excellent performance characteristics:

  • ROC curve analysis shows AUC of 0.98

  • Sensitivity: 91.2%

  • Specificity: 98.1%

  • Positive predictive value: 98.0%

  • Negative predictive value: 91.5%

• Resolution of diagnostic ambiguities: This method is particularly valuable in cases with:

  • Normal ceruloplasmin levels (>20 mg/dL), where 87.5% of WD patients still show ATP7B deficiency

  • Ambiguous genetic results, where 94% of patients demonstrate ATP7B deficiency

• Analytical performance:

This approach effectively supplements the Leipzig scoring system, providing a non-invasive diagnostic method that reduces ambiguities from ceruloplasmin measurements and genetic analysis .

What methodological insights have emerged from ATP7B peptide measurement studies?

The development of peptide measurement techniques for ATP7B has yielded important methodological considerations:

• Selection of signature peptides: Research has identified two key ATP7B peptides (ATP7B 887 and ATP7B 1056) that serve as effective surrogates for measuring ATP7B protein levels .

• Immunoaffinity enrichment approach: Anti-peptide antibodies concentrate extremely low-concentration peptide targets from complex matrices like dried blood spots through immunoaffinity enrichment coupled to selected reaction monitoring (immuno-SRM) mass spectrometry .

• Sample stability: ATP7B peptides have demonstrated stability in DBS samples, making this a practical approach for clinical sample collection and transport.

• Internal standards: For accurate quantification, isotopically labeled internal standards containing 13C and 15N C-terminal lysine (+8 Da) or arginine (+10 Da) are essential .

• Validation metrics: Method development requires careful determination of:

  • Lower limit of detection (LLOD)

  • Lower limit of quantification (LLOQ)

  • Intra- and inter-assay coefficient of variation (CV)

  • Positive and negative predictive values

This methodology represents a significant advance in protein quantification techniques applicable to diagnostic laboratory settings.

How does ATP7B localization change in response to copper levels, and how can researchers track this?

ATP7B exhibits dynamic intracellular trafficking in response to changing copper levels:

• Basal conditions (low copper): Under normal conditions, ATP7B predominantly localizes to the trans-Golgi network (TGN) .

• Elevated copper exposure: When cells encounter high copper levels, ATP7B redistributes to cytoplasmic vesicles, specifically to late endosomes .

• Copper removal: Upon restoration of normal copper levels, ATP7B recycles back to the trans-Golgi network .

To visualize and track this dynamic localization, researchers can:

• Use GFP-ATP7B or ATP7B-DsRed fusion proteins for live-cell imaging

• Compare ATP7B distribution with organelle markers like Rab7 (late endosomes), Lamp1 (lysosomes), and GalT (Golgi)

• Employ U18666A, which induces Niemann-Pick C phenotype, to modulate intracellular vesicle traffic and observe effects on ATP7B localization

Immunofluorescence studies have shown that ATP7B appears in a punctate vesicular pattern around the nucleus, with a distribution distinct from the compact Golgi ribbon pattern of GalT. While ATP7B distribution shows similarities to Lamp1 (late endosome/lysosome marker), ATP7B is more restricted to the perinuclear region .

What experimental approaches can reveal ATP7B trafficking defects in Wilson disease mutants?

To investigate ATP7B trafficking abnormalities associated with Wilson disease mutations:

• Expression systems: Create stable or transient cell lines expressing wild-type or mutant ATP7B variants in hepatic cell lines (HepG2, Huh7) or other easily transfectable cells.

• Visualization methods:

  • Fluorescent protein fusions (GFP-ATP7B, ATP7B-DsRed)

  • Immunofluorescence with ATP7B antibodies

  • Confocal microscopy for high-resolution imaging

• Copper challenge experiments:

  • Treat cells with copper chelators (bathocuproine disulfonate) to observe localization under low copper conditions

  • Treat with copper sulfate to induce trafficking to vesicular compartments

  • Monitor return to original location after copper removal

• Co-localization studies: Compare ATP7B distribution with:

  • TGN markers (TGN38, GalT)

  • Endosomal/lysosomal markers (Rab7, Lamp1, NPC1)

  • Plasma membrane markers

• Biochemical fractionation: Complement imaging with subcellular fractionation and Western blotting to quantify ATP7B distribution across cellular compartments.

Studies using these approaches have demonstrated that many disease-causing ATP7B mutations (including common variants like p.H1069Q, p.R778L, p.M645R, and p.E1064A) result in undetectable or significantly reduced levels of ATP7B protein .

What are common challenges when using ATP7B antibodies, and how can they be addressed?

Researchers working with ATP7B antibodies frequently encounter these challenges:

• High molecular weight detection issues:

  • Problem: Poor transfer of the large (157 kDa) ATP7B protein

  • Solution: Use low percentage gels (6-8%) and wet transfer at low voltage for extended periods; consider specialized transfer systems for high molecular weight proteins

• Variable expression levels:

  • Problem: Low endogenous expression in non-hepatic tissues

  • Solution: Start with liver tissue or hepatocyte cell lines; concentrate protein samples; use highly sensitive detection systems like ECL-Plus

• Non-specific binding:

  • Problem: Cross-reactivity with other P-type ATPases

  • Solution: Validate antibody specificity using ATP7B knockout cells or tissues; use peptide competition assays; select antibodies targeting unique regions of ATP7B

• Fixation artifacts in localization studies:

  • Problem: Fixation may alter membrane protein distribution

  • Solution: Compare multiple fixation methods; validate with live-cell imaging using fluorescent protein fusions

• Splice variant detection:

  • Problem: ATP7B has tissue-specific isoforms

  • Solution: Choose antibodies that detect all relevant isoforms or select isoform-specific antibodies depending on research goals; Western blotting may reveal multiple bands

For troubleshooting, peptide competition assays can confirm specificity - pre-incubating the antibody with the immunizing peptide should eliminate specific signals while leaving non-specific binding intact .

How should ATP7B antibodies be validated before use in critical experiments?

Thorough antibody validation is essential before conducting definitive experiments:

• Positive control selection:

  • Use tissues/cells known to express ATP7B (liver, kidney, HepG2 cells)

  • Include recombinant ATP7B protein as a molecular weight reference

• Negative controls:

  • ATP7B knockout or knockdown cells/tissues

  • Tissues known not to express ATP7B

  • Secondary antibody-only controls

• Cross-reactivity assessment:

  • Test in multiple species if cross-species reactivity is claimed

  • Verify lack of signal in ATP7B-deficient samples

• Specificity confirmation:

  • Peptide competition/blocking assays

  • Comparison of results from antibodies targeting different epitopes

  • Correlation with mRNA expression data

• Application-specific validation:

  • For Western blotting: Verify correct molecular weight (approximately 150-157 kDa)

  • For IHC/IF: Confirm expected tissue/cellular distribution

  • For IP: Confirm enrichment of target protein by Western blot analysis

• Batch consistency:

  • Compare new lots with previously validated antibody lots

  • Maintain reference samples for inter-batch comparison

Careful validation prevents misleading results, particularly in studies of Wilson disease where accurate ATP7B detection is diagnostically significant .

How can ATP7B antibodies be used to investigate the relationship between copper metabolism and other diseases?

Beyond Wilson disease, ATP7B antibodies are valuable tools for investigating broader copper metabolism dysfunctions:

• Neurodegenerative disorders:

  • Abnormal copper homeostasis has been implicated in Alzheimer's, Parkinson's, and prion diseases

  • ATP7B antibodies can help assess copper transporter expression in neuronal tissues and determine whether alterations in ATP7B contribute to pathological copper accumulation

• Cancer research:

  • Copper metabolism is frequently dysregulated in various cancers

  • ATP7B overexpression has been observed in certain tumors, potentially contributing to chemotherapy resistance

  • Immunohistochemistry with ATP7B antibodies can evaluate ATP7B levels in tumor tissues compared to normal counterparts

• Metabolic syndrome and liver disease:

  • ATP7B function may be altered in non-alcoholic fatty liver disease (NAFLD)

  • ATP7B antibodies enable assessment of protein expression and localization changes in metabolic disorders

• Drug development:

  • For screening compounds that might restore function to mutant ATP7B proteins

  • In evaluating how therapeutic agents affect ATP7B expression and trafficking

• Interactions with other metal transporters:

  • Co-immunoprecipitation with ATP7B antibodies can identify protein-protein interactions between ATP7B and other transporters or chaperones

  • This helps map the broader network of cellular metal homeostasis mechanisms

These applications require careful experimental design, including appropriate controls and complementary techniques to validate findings beyond antibody-based detection alone.

What are the emerging approaches for studying post-translational modifications of ATP7B using specific antibodies?

Post-translational modifications (PTMs) significantly impact ATP7B function and trafficking, representing an emerging area of research:

• Phosphorylation studies:

  • ATP7B activity is regulated by phosphorylation at multiple sites

  • Researchers can develop or obtain phospho-specific ATP7B antibodies that recognize particular phosphorylated residues

  • These enable tracking of how phosphorylation status changes in response to copper levels or in disease states

• Ubiquitination analysis:

  • Ubiquitination regulates ATP7B degradation and potentially its trafficking

  • Co-immunoprecipitation with ATP7B antibodies followed by ubiquitin-specific antibodies can reveal ubiquitination patterns

  • This technique helps assess how mutations or cellular conditions affect ATP7B stability

• Glycosylation assessment:

  • ATP7B undergoes N-glycosylation, important for proper folding and trafficking

  • Researchers can use glycosidase treatments combined with ATP7B immunoblotting to evaluate glycosylation status

  • Changes in glycosylation pattern may explain trafficking defects in certain Wilson disease mutations

• Copper-binding status:

  • ATP7B conformational changes occur upon copper binding

  • Developing conformation-specific antibodies that distinguish copper-bound from copper-free ATP7B would represent a significant advance

  • Such tools would enable direct monitoring of ATP7B functional status in situ

• Cross-linking mass spectrometry approaches:

  • Combining ATP7B immunoprecipitation with cross-linking and mass spectrometry

  • This technique can reveal ATP7B structural changes associated with different functional states or disease-causing mutations

These advanced approaches require sophisticated antibody development and validation strategies but offer unprecedented insights into ATP7B regulation and function in health and disease.